GILDER GAGNON HOWE & CO LLC - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 4 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
GILDER GAGNON HOWE & CO LLC ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q3 2023$341,955
-23.2%
9,592
-0.6%
0.01%
-16.7%
Q2 2023$445,062
+47.9%
9,648
+91.1%
0.01%
+20.0%
Q2 2022$301,000
-38.6%
5,048
-25.2%
0.01%0.0%
Q1 2022$490,000
-58.5%
6,751
-51.9%
0.01%
-28.6%
Q4 2021$1,180,000
-27.6%
14,034
-22.3%
0.01%
-12.5%
Q3 2021$1,629,000
-6.9%
18,060
-1.5%
0.01%
-11.1%
Q2 2021$1,749,000
-16.5%
18,344
-0.2%
0.01%
-18.2%
Q1 2021$2,094,000
-35.0%
18,388
-21.0%
0.01%
-31.2%
Q4 2020$3,223,000
+564.5%
23,284
+240.4%
0.02%
+100.0%
Q3 2016$485,000
+44.8%
6,840
-0.0%
0.01%
+14.3%
Q2 2016$335,000
-22.8%
6,842
-0.2%
0.01%
-22.2%
Q1 2016$434,0000.0%6,855
+61.9%
0.01%
+50.0%
Q2 2015$434,000
-2.5%
4,235
-40.9%
0.01%0.0%
Q1 2015$445,000
+38.6%
7,162
-2.2%
0.01%
+20.0%
Q4 2014$321,000
-25.0%
7,324
-3.2%
0.01%
-16.7%
Q3 2014$428,000
+25.5%
7,567
-0.3%
0.01%
+20.0%
Q2 2014$341,000
-65.6%
7,589
-62.6%
0.01%
-64.3%
Q1 2014$992,00020,2910.01%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q4 2023
NameSharesValueWeighting ↓
Abingworth LLP 38,100$2,928,0001.67%
Opaleye Management Inc. 80,000$6,149,0001.59%
HIGHLINE CAPITAL MANAGEMENT, L.P. 410,000$31,517,0001.06%
Opus Point Partners Management, LLC 6,311$485,0001.05%
SECTOR GAMMA AS 68,015$5,228,0000.87%
Capital Impact Advisors, LLC 27,074$2,061,0000.76%
FORTALEZA ASSET MANAGEMENT INC/ 1,130$87,0000.71%
CAPITAL INTERNATIONAL LTD /CA/ 46,957$3,610,0000.63%
Virtus ETF Advisers LLC 8,794$676,0000.60%
Rock Springs Capital Management LP 200,000$15,374,0000.59%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders